{"meshTagsMajor":["United States Food and Drug Administration","Drug Approval"],"meshTags":["Humans","Neuroblastoma","United States","United States Food and Drug Administration","Antibodies, Monoclonal","Drug Approval","Antineoplastic Agents"],"meshMinor":["Humans","Neuroblastoma","United States","Antibodies, Monoclonal","Antineoplastic Agents"],"publicationTypes":["News"],"abstract":"The FDA approved the use of dinutuximab, in combination with three other agents, for high-risk neuroblastoma, offering patients the first major new treatment in more than a decade. ","title":"Dinutuximab approved for high-risk neuroblastoma.","pubmedId":"25851859"}